Stockscreener 앱 받기
25.04
1.14%
-0.29
전일 마감가:
$25.33
열려 있는:
$25.04
하루 거래량:
2.37M
Relative Volume:
0.73
시가총액:
$3.57B
수익:
$62.38M
순이익/손실:
$-101.59M
주가수익비율:
-28.97
EPS:
-0.8644
순현금흐름:
$-139.93M
1주 성능:
+20.97%
1개월 성능:
+40.04%
6개월 성능:
+173.06%
1년 성능:
+1,856%
1일 변동 폭
$24.51
$26.00
1주일 범위
$19.68
$26.00
52주 변동 폭
$1.03
$26.00
Tango Therapeutics Inc Stock (TNGX) Company Profile
명칭
Tango Therapeutics Inc
전화
(857) 320-4900
주소
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
25.04 | 3.61B | 62.38M | -101.59M | -139.93M | -0.8644 |
VRTX
Vertex Pharmaceuticals Inc
|
435.65 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.00 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.13 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
320.70 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-02 | 개시 | Canaccord Genuity | Buy |
| 2026-02-23 | 개시 | Mizuho | Outperform |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-17 | 개시 | Jefferies | Buy |
| 2024-04-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-12 | 개시 | Piper Sandler | Overweight |
| 2023-12-08 | 개시 | B. Riley Securities | Buy |
| 2022-10-20 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 개시 | SVB Leerink | Outperform |
모두보기
Tango Therapeutics Inc 주식(TNGX)의 최신 뉴스
Tango Therapeutics (TNGX) R&D president exercises options and sells stock - Stock Titan
Tango Therapeutics president sells $961k in stock - Investing.com
Tudor Investment Corp ET AL Acquires New Holdings in Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat - Sahm
Tango Therapeutics Overhauls Finance Leadership Amid Clinical Push - TipRanks
Tango Therapeutics names Matthew Gall as chief financial officer By Investing.com - Investing.com South Africa
New CFO and senior leaders join Tango Therapeutics (NASDAQ: TNGX) - Stock Titan
Tango Therapeutics names Matthew Gall as chief financial officer - Investing.com
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of ... - Bluefield Daily Telegraph
Tango brings in 3 executives to speed a pancreatic cancer drug toward approval - Stock Titan
Tango Therapeutics is the best performing healthcare stock in March - MSN
Tango Therapeutics (TNGX) price target increased by 32.09% to 20.06 - MSN
Tango Therapeutics (NASDAQ:TNGX) Reaches New 52-Week HighHere's What Happened - MarketBeat
Tango Therapeutics Inc stock hits all-time high of 22.21 USD - Investing.com Canada
Tango Therapeutics Inc stock hits all-time high of 22.21 USD By Investing.com - Investing.com South Africa
Leerink raises Tango Therapeutics stock price target on PDAC data By Investing.com - Investing.com South Africa
Update Report: Is Tango Therapeutics Inc in a long term uptrendCEO Change & Smart Money Movement Tracker - baoquankhu1.vn
Leerink raises Tango Therapeutics stock price target on PDAC data - Investing.com
Performance Recap: Will Tango Therapeutics Inc benefit from rising consumer demand2026 Macro Moves & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Tango Therapeutics (NASDAQ:TNGX) Shares Gap UpTime to Buy? - MarketBeat
Momentum Shift: Will Tango Therapeutics Inc stock go up in YEARWeekly Profit Recap & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Moving Averages: Will Tango Therapeutics Inc benefit from rising consumer demandM&A Rumor & Weekly High Momentum Picks - baoquankhu1.vn
TNGX Should I Buy - Intellectia AI
Stifel and Jefferies raise targets on Tango Therapeutics (TNGX) - MSN
Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets - The Globe and Mail
Symbol lookup from Yahoo Finance - Yahoo Finance Australia
Tango Therapeutics (TNGX) sees cautious analyst optimism following earnings - MSN
Stifel and Jefferies Raise Targets on Tango Therapeutics (TNGX) - Insider Monkey
Tango Therapeutics (NASDAQ:TNGX) Trading Down 4.3%Here's What Happened - marketbeat.com
TNGX stock hits record high on inking collaboration deal with ERAS - MSN
10 Best Performing Stocks of Q1 2026 to Watch for Q2 - Insider Monkey
Does Tango Therapeutics’ (TNGX) New ATM Plan Reframe Its Long‑Term Funding and Trial Risk Balance? - Sahm
Canaccord Genuity initiates coverage of Tango Therapeutics (TNGX) with buy recommendation - MSN
Tango Therapeutics stock hits all-time high at 21.84 USD By Investing.com - Investing.com Australia
Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells 27,000 Shares of Stock - MarketBeat
Tango a new Buy at Canaccord Genuity on 2026 catalysts - MSN
Tango Therapeutics president sells $572k in shares By Investing.com - Investing.com Canada
Tango Therapeutics (NASDAQ: TNGX) president sells 27,000 shares - Stock Titan
Tango stock is a new Buy at Canaccord Genuity (TNGX:NASDAQ) - Seeking Alpha
Tango Therapeutics (NASDAQ:TNGX) Reaches New 12-Month HighHere's Why - MarketBeat
Tango Therapeutics stock hits all-time high at 21.84 USD - Investing.com
Canaccord Genuity Group Begins Coverage on Tango Therapeutics (NASDAQ:TNGX) - MarketBeat
CCORF Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $30 - Moomoo
Tango Therapeutics Inc (TNGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.45%
0.77%
자본화:
|
볼륨(24시간):